Labreportnew

Visit ID : VSP72319 UHID/MR No : VSP.
0000072302
Patient Name : Mrs. G MONA Client Code : 79
Age/Gender : 35 Y 0 M 0 D /F Barcode No : 10634644
DOB : Registration : 20/Aug/2023 01:51PM
Ref Doctor : SELF Collected : 20/Aug/2023 02:42PM
Client Name : YODA DIAGNOSTICS VIZAG Received : 20/Aug/2023 03:24PM
Client Add : 15-12-4,2nd floor,opp Sagar Du Reported : 20/Aug/2023 06:21PM
Hospital Name :
DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Biological. Ref. Range Method
BLOOD GROUP ABO & RH Typing

Sample Type : WHOLE BLOOD EDTA
ABO O
Rh Typing POSITIVE
Method : Hemagglutination Tube method by forward and reverse grouping
COMMENTS:
The test will detect common blood grouping system A, B, O, AB and Rhesus (RhD). Unusual blood groups or rare subtypes
will not be detected by this method. Further investigation by a blood transfusion laboratory, will be necessary to identify
such groups.
Disclaimer: There is no trackable record of previous ABO & RH test for this patient in this lab. Please correlate with
previous blood group findings. Advsied cross matching before transfusion
Verified By : Approved By :
JAGANMOHAN
Page 1 of 16
Visit ID : VSP72319 UHID/MR No : VSP.0000072302
Hospital Name :
DEPARTMENT OF HAEMATOLOGY
CBC(COMPLETE BLOOD COUNT)

HAEMOGLOBIN (HB) 10.5 g/dl 12.0 - 15.0 Cyanide-free SLS
method
RBC COUNT(RED BLOOD CELL COUNT) 3.98 million/cmm 4.50 - 5.50 Impedance
PCV/HAEMATOCRIT 30.8 % 40.0 - 50.0 RBC pulse height
detection
MCV 77.3 fL 83 - 101 Automated/Calculated
MCH 26.5 pg 27 - 32 Automated/Calculated
MCHC 34.3 g/dl 32 - 35 Automated/Calculated
RDW - CV 14.9 % 11.0-16.0 Automated Calculated
RDW - SD 45.3 fl 35.0-56.0 Calculated
MPV 10.5 fL 6.5 - 10.0 Calculated
PDW 15.8 fL 8.30-25.00 Calculated
PCT 0.277 % 0.15-0.62 Calculated
TOTAL LEUCOCYTE COUNT 6,450 cells/ml 4000 - 11000 Flow Cytometry
DLC (by Flow cytometry/Microscopy)
NEUTROPHIL 62 % 40 - 70 Impedance
LYMPHOCYTE 29.8 % 20 - 40 Impedance
EOSINOPHIL 1.9 % 01 - 06 Impedance
MONOCYTE 6.2 % 02 - 08 Impedance
BASOPHIL 0.1 % 0-1 Impedance
PLATELET COUNT 2.64 Lakhs/cumm 1.50 - 4.10 Impedance
JAGANMOHAN
Page 2 of 16
Hospital Name :
DEPARTMENT OF BIOCHEMISTRY
THYROID PROFILE (T3,T4,TSH)

Sample Type : SERUM
T3 0.98 ng/ml 0.87-1.78 CLIA
T4 12.03 ug/dl 4.82-15.65 CLIA
TSH 2.57 ulU/mL 0.30 - 5.60 CLIA
INTERPRETATION:
1. Serum T3, T4 and TSH are the measurements form three components of thyroid screening panel and are useful in diagnosing various
disorders of thyroid gland function.
2. Primary hyperthyroidism is accompanied by elevated serum T3 and T4 values along with depressed TSH levels.
3. Primary hypothyroidism is accompanied by depressed serum T3 and T4 values and elevated serum TSH levels.
4. Normal T4 levels accompanied by high T3 levels are seen in patients with T3 thyrotoxicosis. Slightly elevated T3 levels may be found in
pregnancy and in estrogen therapy while depressed levels may be encountered in severe illness, malnutrition, renal failure and during
therapy with drugs like propanolol and propylthiouracil.
5. Although elevated TSH levels are nearly always indicative of primary hypothyroidism, rarely they can result from TSH secreting pituitary
tumors (secondary hyperthyroidism).
6. Low levels of Thyroid hormones (T3, T4 & FT3, FT4) are seen in cases of primary, secondary and tertiary hypothyroidism and sometimes
in non-thyroidal illness also.
7. Increased levels are found in Grave’s disease, hyperthyroidism and thyroid hormone resistance.
8. TSH levels are raised in primary hypothyroidism and are low in hyperthyroidism and secondary hypothyroidism.
9. REFERENCE RANGE :
TSH in uIU/mL
PREGNANCY
1st Trimester 0.60 - 3.40
2nd Trimester 0.37 - 3.60
3rd Trimester 0.38 – 4.04
( References range recommended by the American Thyroid Association)
Comments:
1. During pregnancy, Free thyroid profile (FT3, FT4 & TSH) is recommended.
2. TSH levels are subject to circadian variation, reaches peak levels between 2-4 AM and at a minimum between 6-10 PM. The
variation of the day has influence on the measured serum TSH concentrations.
JAGANMOHAN
Page 3 of 16
Hospital Name :
LIVER FUNCTION TEST(LFT)

Sample Type : SERUM
TOTAL BILIRUBIN 0.63 mg/dl 0.3 - 1.2 JENDRASSIK &
GROFF
CONJUGATED BILIRUBIN 0.17 mg/dl 0 - 0.2 DPD
UNCONJUGATED BILIRUBIN 0.46 mg/dl Calculated
S.G.O.T 14 U/L < 35 KINETIC
WITHOUT P5P-
IFCC
S.G.P.T 9 U/L < 35 KINETIC
WITHOUT P5P-
IFCC
ALKALINE PHOSPHATASE 67 U/L 30 - 120 IFCC-AMP
BUFFER
TOTAL PROTEINS 7.4 gm/dl 6.0 - 8.0 Biuret
ALBUMIN 4.3 gm/dl 3.5 - 5.2 BCG
GLOBULIN 3.0 gm/dl Calculated
A/G RATIO 1.42 Calculated
JAGANMOHAN
Page 4 of 16
Hospital Name :
CALCIUM - TOTAL
Sample Type : SERUM
SERUM TOTAL CALCIUM 8.5 mg/dl 8.8 - 10.6 Arsenazo III
INTERPRETATION:
-Calcium level is increased in patients with hyperparathyroidism, Vitamin D intoxication, metastatic bone tumor, milk-alkali
syndrome, multiple myeloma, Paget’s disease.
-Calcium level is decreased in patients with hemodialysis, hypoparathyroidism (primary, secondary), vitamin D deficiency,
acute pancreatitis, diabetic Keto-acidosis, sepsis, acute myocardial infarction (AMI), malabsorption, osteomalacia, renal
failure, rickets.
JAGANMOHAN
Page 5 of 16
Hospital Name :
LIPID PROFILE
Sample Type : SERUM
TOTAL CHOLESTEROL 170 mg/dl Desirable : 0-200 Cholesterol
Borderline :200 – 239 oxidase/peroxidase
High : >=240
H D L CHOLESTEROL 64 mg/dl > 40 Enzymatic/
Immunoinhibiton
L D L CHOLESTEROL 96.2 mg/dl Optimal - 70-106 Enzymatic Selective
Near Optimal/Aboveoptimal - Protein
100 - 129 mg/dl
Borderline High - 130 - 159
mg/dl
TRIGLYCERIDES 49 mg/dl Normal : < 150 GPO
BorderLine : 150 - 199
High : 200-499
VLDL 9.8 mg/dl 15 - 30 Calculated
T. CHOLESTEROL/ HDL RATIO 2.66
TRIGLYCEIDES/ HDL RATIO 0.77 Ratio < 2.0 Calculated
NON HDL CHOLESTEROL 106 mg/dl < 130 Calculated
Interpretation
NATIONAL LIPID ASSOCIATION TOTAL LDL NON HDL
TRIGLYCERIDE
RECOMMENDATIONS (NLA-2014) CHOLESTEROL CHOLESTEROL CHOLESTEROL
Optimal <200 <150 <100 <130
Above Optimal - - 100-129 130 - 159
Borderline High 200-239 150-199 130-159 160 - 189
High >=240 200-499 160-189 190 - 219
Very High - >=500 >=190 >=220
REMARKS Cholesterol : HDL Ratio
Low risk 3.3-4.4
Average risk 4.5-7.1
Moderate risk 7.2-11.0
High risk >11.0
Note:
1.Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are
recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol
2. NLA-2014 identifies Non HDL Cholesterol(an indicator of all atherogenic lipoproteins such as LDL , VLDL, IDL, Lpa, Chylomicron
JAGANMOHAN
Page 6 of 16
Hospital Name :
remnants)along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify
treatment goals for LDL &Non HDL.
3.Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved
4. Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered among patients with moderate risk for ASCVD
for risk refinement
JAGANMOHAN
Page 7 of 16
Hospital Name :
25 HYDROXY VITAMIN D
Sample Type : SERUM
25 HYDROXY VITAMIN D 26.4 ng/ml 30 - 70 CLIA
INTERPRETATION:
LEVEL REFERENCE RANGE

Deficiency (serious deficient) < 10 ng/ml
Insufficiency (Deficient) 10-30 ng/ml
Sufficient (adequate) 30-70 ng/ml
Toxicity > 100 ng/ml
DECREASED LEVELS:
-Deficiency in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and Tetany.
-Inadequate exposure to sunlight.
-Dietary deficiency.
-Vitamin D malabsorption.
-Severe Hepatocellular disease.
-Drugs like Anticonvulsants.
-Nephrotic syndrome.
INCREASED LEVELS:
-Vitamin D intoxication.
COMMENTS:
-Vitamin D (Cholecalciferol) promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Vitamin
D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major circulating form and has longer half
life (2-3 weeks) than 1, 25 Dihydronxy vitamin D (5-8 hrs).
-The assay measures D3 (Cholecaciferol) metabolites of vitamin D.
-25 (OH) D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
-Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 ng/mL.
-It shows seasonal variation, with values being 40-50% lower in winter than in summer.
-Levels vary with age and are increased in pregnancy.
-This is the recommended test for evaluation of vitamin D intoxication.
JAGANMOHAN
Page 8 of 16
Hospital Name :
HBA1C
HBA1c RESULT 5.8 % Normal Glucose tolerance HPLC
(non-diabetic): 4.0 - 6.0 %
Pre-diabetic: 6.0-6.5%
Diabetic Mellitus: >6.5%
ESTIMATED AVG. GLUCOSE 120 mg/dl
Note:
1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under
good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but
now poorly controlled .
2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no
significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive
co-morbid conditions,targeting a goal of < 7.0 % may not be appropriate.
HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long
term glycemic control .
JAGANMOHAN
Page 9 of 16
Hospital Name :
VITAMIN B12
Sample Type : SERUM
VITAMIN B12 234 pg/mL 120 - 914 pg/mL CLIA
COMMENTS:
Results may differ between laboratories due to variation in population and test method. Vitamin B12 is implicated in the formation of
myelin, and along with Folate is required for DNA synthesis. The most prominent source of B12 for humans is meat while untreated fresh
water can also be a source.
Megaloblastic anaemia has been found to be due to B12 deficiency, a major cause being Pernicious anemia due to poor B12 uptake
resulting in below normal serum levels. Other conditions related to low B12 levels include iron deficiency anemia, pregnancy, vegetarianism,
partial gastrectomy, ileal damage, oral contraceptives, parasitic infestations, pancreatic deficiency, treated epilepsy and advancing age. The
correlation of serum B12 levels and Megaloblastic anemia however is not always clear - some patients with high MCV may have normal B12
levels, while some individuals with B12 deficiency may not have megaloblastic anemia. Disorders renal failure, liver diseases and
myeloproliferative diseases may have elevated vitamin B12 levels.
LIMITATIONS:
For diagnostic purposes, the B12 results should be used in conjunction with other data; e.g.; symptoms results of other testing, clinical
impressions, etc.
If the B12 level is inconsistent with clinical evidence, additional testing is suggested to confirm the result.
JAGANMOHAN
Page 10 of 16
Hospital Name :
FBS (GLUCOSE FASTING)

Sample Type : FLOURIDE PLASMA
FASTING PLASMA GLUCOSE 91 mg/dl 70 - 100 HEXOKINASE
INTERPRETATION:
Increased In
Diabetes Mellitus
Stress (e.g., emotion, burns, shock, anesthesia)
Acute pancreatitis
Chronic pancreatitis
Wernicke encephalopathy (vitamin B1 deficiency)
Effect of drugs (e.g. corticosteroids, estrogens, alcohol, phenytoin, thiazides)
Decreased In
Pancreatic disorders
Extrapancreatic tumors
Endocrine disorders
Malnutrition
Hypothalamic lesions
Alcoholism
Endocrine disorders
JAGANMOHAN
Page 11 of 16
Hospital Name :
SERUM CREATININE
Sample Type : SERUM
SERUM CREATININE 0.81 mg/dl 0.60 - 1.30 KINETIC-JAFFE
Increased In:
Diet: ingestion of creatinine (roast meat), Muscle disease: gigantism, acromegaly,

Impaired kidney function.
Decreased In:
Pregnancy: Normal value is 0.4-0.6 mg/dL. A value >0.8 mg/dL is abnormal and should alert the clinician
to further diagnostic evaluation.
Creatinine secretion is inhibited by certain drugs (e.g., cimetidine, trimethoprim).
JAGANMOHAN
Page 12 of 16
Hospital Name :
SERUM UREA
Sample Type : SERUM
SERUM UREA 19.5 mg/dL 13 - 43 Urease GLDH
Determination of blood urea is the most widely used screening test for renal function. When used in conjunction with serum
creatinine determinations it can aid in the differential diagnosis of the three types of azotemia: prerenal, renal and postrenal.
Elevations in blood urea concentration are seen in inadequate renal perfusion, shock, diminished blood volume (prerenal
causes), chronic nephritis, nephrosclerosis, tubular necrosis, glomerular nephritis (renal causes) and urinary tract obstruction
(postrenal causes). Transient elevations may also be seen during periods of high protein intake. Unpredictable levels occur
with liver diseases.
JAGANMOHAN
Page 13 of 16
Hospital Name :
GGT (GAMMA GLUTAMYL TRANSPEPTIDASE)

Sample Type : SERUM
GGT 8 U/L 0 - 55.0 KINETIC-IFCC
INTERPRETATION:
GGT functions in the body as a transport molecule, helping to move other molecules around the body. It plays a significant role in helping
the liver metabolize drugs and other toxins. Increased GGT include overuse of alcohol, chronic viral hepatitis, lack of blood flow to the liver,
liver tumor, cirrhosis, or scarred liver, overuse of certain drugs or other toxins, heart failure, diabetes, pancreatitis, fatty liver disease.
JAGANMOHAN
Page 14 of 16
Hospital Name :
URIC ACID -SERUM

Sample Type : SERUM
SERUM URIC ACID 4.8 mg/dl 2.6 - 6.0 URICASE - PAP
Uric acid is the final product of purine metabolism in the human organism. Uric acid measurements are used in the diagnosis
and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation or
other wasting conditions, and of patients receiving cytotoxic drugs.
JAGANMOHAN
Page 15 of 16
Hospital Name :
IRON / TIBC
Sample Type : SERUM
SERUM IRON LEVELS 56.38 ug/dl 60-180 Ferrozine
TOTAL IRON BINDING CAPACITY 392 ug/dl 250-450 Colorimetric
UIBC 335.7 ug/dL 120 - 470 Nitroso- PSAP
TRANSFERRIN SATURATION INDEX 14.4 % 14 - 50 Calculated
About :
Ingested iron is absorbed primarily from the intestinal tract and is temporarily stored in the mucosal cells as ferritin (Fe[III]).
Ferritin provides a soluble protein shell to encapsulate a complex of insoluble ferric hydroxide-ferric phosphate. On demand,
iron is released into the blood by mechanisms that are not clearly understood, to be transported as Fe(III)-transferrin.
Transferrin is the primary plasma iron transport protein, which binds iron strongly at physiological pH. Transferrin is
generally only 25% to 30% saturated with iron. The additional amount of iron that can be bound is the unsaturated iron-
binding capacity (UIBC). The total iron-binding capacity (TIBC) can be indirectly determined using the sum of the serum iron
and UIBC. Knowing the molecular weight of the transferrin and that each molecule of transferrin can bind 2 atoms of iron,
TIBC and transferrin concentration is interconvertible.
Percent saturation is usually normal or decreased in persons who are iron deficient, pregnant, or are taking oral
contraceptive medications. Persons with chronic inflammatory processes, hemochromatosis, or malignancies generally
display low transferrin.
Serum iron, total iron-binding capacity, and percent saturation are widely used for the diagnosis of iron deficiency. However,
serum ferritin is a much more sensitive and reliable test for demonstration of iron deficiency.
References
https://www.mayocliniclabs.com/test-catalog/overview/34624#Clinical-and-Interpretive
*** End Of Report ***
JAGANMOHAN
Page 16 of 16

Labreportnew

Uploaded by

Copyright:

Available Formats

Labreportnew

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Labreportnew

Uploaded by

Copyright:

Available Formats

Visit ID : VSP72319 UHID/MR No : VSP.

BLOOD GROUP ABO & RH Typing

CBC(COMPLETE BLOOD COUNT)

THYROID PROFILE (T3,T4,TSH)

LIVER FUNCTION TEST(LFT)

LEVEL REFERENCE RANGE

FBS (GLUCOSE FASTING)

Diet: ingestion of creatinine (roast meat), Muscle disease: gigantism, acromegaly,

GGT (GAMMA GLUTAMYL TRANSPEPTIDASE)

URIC ACID -SERUM

* End Of Report *

You might also like